The University of Miami uses Qynapse AI technology to investigate the effects of COVID-19 on neuroimaging markers of cognitive decline

BOSTON, September 7, 2022 /PRNewswire/ — Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-driven neuroimaging analysis platform for central nervous system (CNS) disorders, is pleased to announce a collaboration project with the university of miami Miller School of Medicine to examine the effects of COVID-19 on vascular contributions to cognitive impairment and dementia (VCID), funded by the National Institute of Health (NIH).

Covid-19 has infected more than 540 million people and has contributed to more than 6.32 million deaths worldwide. As a multisystem disease, neurological symptoms have been observed to varying degrees, including strokes, headaches, seizures, anosmia, and dysgeusia. However, the association between COVID-19 and cognitive decline remains poorly understood.

To investigate this topic, the university of miami is recruiting 250 patients who will undergo in-depth phenotyping through clinical, neuropsychological, MRI, and biological data acquisition with a 24-month follow-up visit. Qynapse’s QyScore® AI solution, an FDA-cleared software that provides automated segmentation and quantification of regional brain and white matter hyperintensity volumes, will be implemented in this study to generate MRI brain imaging analysis fast, precise and objective.

“We look forward to leveraging Qynapse’s advanced AI tool to improve the quality of the study’s brain imaging analysis and facilitate the discovery of new insights into the potential impacts of COVID-19 on vascular contributions to cognitive decline and dementia.” said James E GalvinMD, MPH, director of the Comprehensive Center for Brain Health at university of miami Miller School of Medicine Department of Neurology and principal investigator of the study.

Bringing artificial intelligence to further CNS research, Qynapse, Dr. Galvin and the university of miami have signed another agreement in 2021 for two studies in dementia and Parkinson’s disease. The first is a Multicultural Community Dementia Screening study enrolling 500 people analyzed with Qynapse’s MRI, amyloid and tau PET neuroimaging platform and the second to investigate the neuroanthmic correlates of Parkinson’s Disease Dementia, which is funded by through the Michael J Fox Foundation.

“Prof. Galvin and his team are leading such important work on this trilogy of devastating diseases and we are very excited to bring our artificial intelligence and advanced neuroimaging solutions to deliver quantifiable insights into these conditions that affect so many lives,” he said. Elizabeth GordonPh.D., scientific director of Qynapse.

About Qynapse

Qynapse Inc. is a medical technology company commercializing a proprietary AI-powered neuroimaging software platform, creating the potential for earlier clinical accuracy on the front lines of CNS disease.

Qynapse’s flagship, FDA-cleared QyScore® solution adds the potential for more accurate and objective brain scan analysis. Qynapse’s predictive artificial intelligence technology, QyPredict®, available for research only, has the potential to predict the trajectory of disease and improve the selection of specific patients in clinical trials.

Qynapse is headquartered in Francein the United States and in Canada.

Find more about Qynapse solutions at: https://qynapse.com/

Contact: Ruizhe Huang – [email protected]

Logo: https://mma.prnewswire.com/media/1628911/QYNAPSE_Logo.jpg
Logo: https://mma.prnewswire.com/media/1886935/UHealth_Logo.jpg

QYNAPSE SOURCE

See also  Why skimping on voice AI tech could cost banks billions

Leave a Comment